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Congenital adrenal hyperplasia (CAH), most commonly due to 21-hydroxylase deﬁciency (21OHD), has been studied by pediatric
endocrinologists for decades. Advances in the care of these patients have enabled many of these children to reach adulthood. In
contrast to the course and management of the disease in childhood, little is known about CAH in adults. In many patients, the
proclivity to salt-wasting crises decreases. Linear growth ceases, and reproductive function becomes an issue. Most importantly,
management must minimize the potential for long-term consequences of conventional therapies. Here we review the existing
literature regarding comorbidities of adults with 21OHD, goals of treatment, and approaches to therapy, with an emphasis on
need for improved management strategies.
1.Introduction
As discussed elsewhere, the congenital adrenal hyperplasias
(CAHs) are genetic defects in cortisol biosynthesis. Low
cortisol removes feedback inhibition of adrenocorticotropin
(ACTH) secretion, which causes adrenal hyperplasia. The
clinical consequences of CAH derive from both the shunting
of cortisol precursors along other pathways and the biologi-
cal activities of these precursors and their unusual metabo-
lites, which accumulate above the block. Treatments will
ideally replace the glucocorticoid deﬁciency and normalize
both mineralocorticoid and androgen biosynthesis without
inducing untoward eﬀects from the drugs themselves. The
most common cause of CAH is 21-hydroxylase deﬁciency
(21-OHD) [1], which aﬄicts about 1:15,000 live births [2].
Since the introduction of cortisone therapy by Wilkins et
al. in the early 1950s [3], these children have been able
to survive into adulthood. Now that over a half century
has passed, one would think that abundant information
would have accumulated on the care of adults with CAH,
as is now the case for children [4]. Regrettably, very little
is known about the physiology and management of adults
with CAH, and what is known is essentially limited to 21-
OHD.
1.1. Why Is So Little Known? Genetic disorders, which
manifest with congenital disease, are largely the providence
of pediatrics. With the completion of the Human Genome
Project, internists have become more aware of genetic disor-
ders, but largely the focus has been on susceptibility genes
for cancer, diabetes, and cardiovascular diseases. Training
in the care of patients with congenital biosynthetic defects,
such as glycogen storage diseases and CAH, is generally not
considered an important component of internal medicine
residencies and endocrinology fellowships.
Consequently, few doctors who care for adults, even
those at academic medical centers, are adequately trained or
interested in rare genetic diseases. This scenario is evidently
the case for CAH. Most internal medicine endocrinology
trainees will see only a few patients with CAH, mainly if
they rotate in the pediatric endocrinology clinic, and many
will never see a single adult with CAH during their training.
A search of the NIH CRISP database revealed only a few
grants awarded to the study of CAH in the last 5 years,
none of which were awarded to investigators in departments
of internal medicine. Without interest and research in
academic centers, there is little chance that internal medicine
endocrinology fellows will receive adequate training in
CAH.2 International Journal of Pediatric Endocrinology
1.2.ChildrenAreNotLittleAdults. Theendocrinephysiology
of childhood is dominated by growth and pubertal devel-
opment. Adults do neither, but they do age, and many have
childrenoratleastwishtobecomeparents.Withage,theyare
pronetoallthemaladiesofadultlife,includingheartdisease,
osteoporosis, and cancer. Consequently, the focus and goals
of treatment are quite diﬀerent in adults and children.
Treatment of CAH in infancy and early childhood strives
ﬁrst to prevent salt-wasting and hypotensive crises due to
adrenal insuﬃciency. Treatment of adults with CAH should
be tailored to meet the needs of the patient at the present
time, but with a long-term view of mitigating consequences
of therapy. As a rule, the medications used and intensity of
monitoring will vary as the objectives change with time [5].
1 . 3 .Y o u n gA d u l t sw i t hC h r o n i cD i s e a s e sA r eW e a r yo fS e e i n g
Doctors. This feeling is particularly true if the doctor knows
very little about their condition and shows little interest
or concern for their speciﬁc needs. Many patients with
CAH have stopped seeing physicians altogether and have
discontinued corticosteroid replacement for long periods of
time [6]. Women may become comfortable living in a state
of androgen excess and may even experience fatigue from
testosterone withdrawal if therapy is resumed. Men with
CAHofexperiencefewsymptomsfromreducingorstopping
therapy, until they become seriously ill or their testicular
rests become uncomfortably large. These considerations are
important in understanding the approach to the adult with
CAH, both medically and psychologically.
2. Physiology of CAH inAdults
Many of the general principles are the same as for children
with CAH, but the importance of the various factors is
considerably diﬀerent. All subsequent discussion will be
limited to 21-OHD.
2.1. Basic Adrenal Physiology. Cytochrome P450c21
(CYP21A2) deﬁciency precludes aldosterone and cortisol
synthesis, limiting steroidogenesis to the reactions catalyzed
by 3β-hydroxysteroid dehydrogenase type 2 (3β-HSD2),
cytochrome P450c17 (CYP17A1), and a bit to cytochrome
P450c11β (CYP11B1) (Figure 1(a)). Low cortisol increases
ACTH production, ﬂooding the adrenal steroidogenic
machinery with upstream precursors (Figure 1(b)). Over
time,theadrenalsenlargeduetothechronictrophicstimulus
of ACTH. Consequently, the adult adrenal of a patient with
21-OHD makes large amounts of a few steroids, mainly
progesterone (P4), 17-hydroxyprogesterone (17-OHP),
dehydroepiandrosterone and its sulfate (DHEA[S]), plus
lesser amounts of androstenedione (AD), testosterone (T)
[7], and 21-deoxycortisol—which has little glucocorticoid
or mineralocorticoid activity.
Due to zonation, two critical enzyme activities required
for T synthesis are physically separated in the adrenal gland.
The zona fasciculata cells, which contain 3β-HSD2 activity,
also contain CYP17A1; however, these cells have low 17,20-
lyase activity because expression of the important cofactor
protein cytochrome b5 (b5) is low [8, 9]. In contrast, the
zona reticularis—in which ACTH also stimulates steroid
production—has abundant CYP17A1, b5, and thus high
17,20-lyase activity, but these cells are deﬁcient in 3β-HSD2
and have robust DHEA-sulfotransferase activity (SULT2A1).
Furthermore, the adrenal gland lacks 17β-HSD3, the enzyme
responsible for reduction of AD to T in the testis, but
contains AKR1C3 (17β-HSD5) [7], which has weak activity
in catalyzing this reaction [10]. Consequently, the adrenal
gland of a patient with 21-OHD has high capacity to
synthesize DHEAS, but little of this 19-carbon precursor
escapes the adrenal as T.
Alternativeroutesto5α-reduced,19-carbonsteroidshave
been described in other species [11, 12] .T h e s er o u t e si n v o l v e
the 5α-reduction of 21-carbon pregnanes P4 and 17-OHP,
followed by 3α-reduction, to yield 5α-pregnan-3α-ol-20-
one (allopregnanolone) and its 17α-hydroxy derivative, 5α-
pregnane-3α,1 7 α-diol-20-one (Pdiol). Pdiol is then cleaved
to androsterone by the 17,20-lyase activity of CYP17A1.
Androsterone reduction by 17β-HSD enzymes yields 5α-
androstane-3α,1 7 β-diol (Adiol), which is metabolized by
oxidative 3α-HSD enzymes such as 17β-HSD6 (RODH) [13]
to DHT (Figure 2(b)). Via this pathway, DHT is formed
without the intermediacy of T or AD [14]. Considerable
genetic and biochemical evidence suggests that this route
contributes to DHT formation and genital virilization in
female fetuses with cytochrome P450-oxidoreductase deﬁ-
ciency, presumably due to the accumulation of 17-OHP [15–
18]. In 21-OHD, intra-adrenal 17-OHP accumulates as well;
consequently, this pathway is likely to be important in the
fetus with 21-OHD [19]. In adults with 21-OHD, however,
the pathway may not be very active, due to lower expression
of 5α-reductase activity in the adult adrenal.
2.2. Extra-Adrenal Steroid Metabolism. Based on the above
discussion, the adrenal glands of adults with 21-OHD
producelittleTandhugeamountsofothersteroids,yetnone
are active hormones except for P4. Nevertheless, without
proper treatment, AD, T, and DHT concentrations are high
in women and men with 21-OHD, and a high proportion
of T in men with 21-OHD derives from the adrenal. This T is
producedbyperipheralmetabolismoftheadrenalsecretions,
primarily in the liver but also in skin and even target tissues.
The peripheral metabolism of steroids is more diﬃcult to
deﬁne than the intra-adrenal steroidogenic pathways, due to
redundancy of enzymes, competing routes of metabolism,
and variability amongst individuals. Nevertheless, steroid
sulfatase(STS)ispresentinliver,skin,andmanyothertissues
[20], and these tissues also contain 3β-HSD type 1 [21].
Conversion of AD to T is eﬃciently catalyzed by 17β-HSD3,
but its cognate gene is only expressed in the Leydig cell of
the testis. As mentioned above, 17β-HSD5 also has weak
activityforconversionofADtoT[10],butotherroutesfrom
DHEA to T also exist. DHEA can be reduced by 17β-HSD1,
which is an eﬃcient enzyme [22], to androst-5-ene-3β,1 7 β-
diol, a substrate for 3β-HSDs, yielding T (Figure 2(a)). Even
17β-HSD2, which is thought of as an “inactivating” enzymeInternational Journal of Pediatric Endocrinology 3
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Figure 1: Steroid biosynthesis in 21-OHD. (a): Normal steroid biosynthetic pathways within each zone of the human adrenal gland. The
dashed arrows indicate minor reactions. (b): Altered steroid biosynthesis in 21-OHD. The block (heavy vertical line) shunts precursors to
19-carbon steroids (heavy curved black arrow at left).
by eﬃc i e n t l yc o n v e r t i n gTt oA D[ 23], achieves a pseudo-
equilibrium in intact cells with 1-2% T generated from AD
and increases the apparent potency of AD as an androgen
in model systems [24]. In liver and skin, 5α-reductase type
1[ 25] further activates T to DHT, but T and DHT are
also substrates for UDP-glucuronyl transferases (UGTs),
which conjugate active androgens and their metabolites for
excretion in the urine [26]. Consequently, the route(s) from
DHEA to T even in normal women are not obvious, and the
biochemistry is even more complex in 21-OHD, as androgen
precursor production is very high.
In addition to peripheral conversion of DHEA[S] to
active androgens, P4, which accumulates 2 steps prior to
the block, can be 21-hydroxylated by hepatic cytochromes
P450 [27, 28] to yield 11-deoxycorticosterone (DOC), a
potent mineralocorticoid. The extent and routes of periph-
eral metabolism vary considerably amongst individuals and
might explain to some degree the diﬀerences in disease
control for adults with 21-OHD. Conversely, greater accu-
mulation of P4 can contribute to anovulation and infertility
in women with 21-OHD. For these reasons, not only
the control of steroids exiting the adrenal, but also the4 International Journal of Pediatric Endocrinology
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Figure 2: Alternate and peripheral androgen synthesis pathways. (a): the alternate or “backdoor” pathway to DHT, with intra- and extra-
adrenal compartments demarcated. (b): simpliﬁed diagram of peripheral androgen and estrogen metabolism.
extra-adrenal metabolism of these steroids is an important
considerationinunderstandingthephysiologyofCAHinthe
adult.
3. Management of CAH in Adults
As with physiology, the principles governing the treatment
of adults with CAH share many similarities with those for
childrenwithCAH;however,thediﬀerencesrelatetogrowth,
pubertal development, and fertility. In addition, the care of
adults is often more individualized based on patient choices
than in children.
3.1. General Approach to the Patient. As previously men-
tioned, the treatment goals of patients with 21-OHD evolve
with the transition to adulthood. Salt-wasting crises occur
much less frequently, typically only during a severe con-
current illness. During childhood, tight control prevents
premature somatic growth and development of secondary
sexual characteristics, but both concerns are no longer
germane in adulthood. The three major concerns for the
adult with 21-OHD are: (1) the prevention of adrenal and
gonadal hyperplasia and neoplasia; (2) the prevention of
long-term consequences of adrenal replacement therapies,
and (3) the restoration of fertility in those who desire to
have children. Consequently, the intensity and complexity
of treatment regimen is individualized and changed over
time to meet the needs of the patient and to optimize the
risk/beneﬁt ratio.
Mineralocorticoid replacement with 9α-ﬂudrocortisone
acetate, 0.05–0.2mg/d, is usually continued, with the goal
of a suppressed or low-normal plasma renin activity, which
blunts the hypovolemic drive to ACTH production. In
most developed nations, the sodium content of the adultInternational Journal of Pediatric Endocrinology 5
diet is high, and salt craving in adults with 21-OHD is
uncommon. In fact, children [29] and adults [30]w i t h
21-OHD are prone to develop hypertension, prompting
reduction or rarely discontinuation of mineralocorticoid
dosing, or the paradoxical need for antihypertensive drugs
plus ﬂudrocortisone acetate. To titrate mineralocorticoid
replacement, the serum potassium concentrations, plasma
renin activity, and blood pressure in the sitting and standing
positions are monitored, with the goals of renin as low as
possible, normokalemia, and lack of orthostasis.
Glucocorticoid replacement therapy remains of central
importanceintheadultwith21-OHD,despitethedisturbing
fact that many patients will discontinue or neglect their
treatment for months at a time. Hydrocortisone remains
the safest drug for long-term replacement, as is the case for
other forms of adrenal insuﬃciency. Regimens that require 3
doses a day, as is often used in children to suppress adrenal
19-carbon steroid production, pose compliance diﬃculties
for some adults with busy schedules. Most patients manage
to take 2 doses a day consistently, patterned after doses
used for adrenal insuﬃciency, such as 15–20mg on arising
and 5–10mg after the midday meal. The disadvantage of
such a two-dose regimen is the tendency for ACTH to rise
robustly in the early morning hours prior to the ﬁrst dose,
which worsens control, at least for a few hours until the ﬁrst
dose. In children, several groups have found empirically that
administration of the largest dose at bedtime is associated
withtightestcontrolofadrenalsteroidogenesis.Othergroups
have argued that the half-life of hydrocortisone is so short
that an evening dose is only eﬀective in suppressing the
morning ACTH rise if a highly supraphysiologic dose is
administered, such that hydrocortisone should be given dur-
ing the day only [31]. Addition of an evening dose can cause
poor sleep and worsen weight gain and other glucocorticoid-
related side eﬀects, but not in all patients. Unfortunately,
well-designed and controlled studies comparing various
regimens are lacking, so the clinician is advised to generally
try the safest and most physiologic replacement regimen,
and then to intensify therapy gradually if symptoms and
signs of undertreatment become evident. Sustained-release
hydrocortisone preparations administered once daily with
promising pharmacokinetics have been developed [32], but
these products currently are not widely available.
To simplify dosing and to increase suppression of ACTH,
synthetic glucocorticoids such as prednisone, prednisolone,
methylprednisolone, and dexamethasone may be employed.
The problem with these drugs is that long-term usage
almost invariably results in iatrogenic Cushing syndrome,
due to their potency and long half-life. Dexamethasone
needs only to be given once daily, with bedtime adminis-
tration being the most eﬀe c t i v em e a n st os u p p r e s sA C T H
and adrenal 19-carbon steroid production [31]. In fact,
the suppressive eﬀect of single dose of dexamethasone
on DHEAS production often lasts longer than 24 hours.
Prednisolone or prednisone may also be used once daily
as in adrenal insuﬃciency [33], but divided doses may
be better in certain situations discussed below. Combined
regimens, using more potent steroids only a few days per
week, are more complicated, but this approach features
the advantage of mitigating many of the side eﬀects of
taking these drugs chronically while utilizing their capacity
to suppress DHEAS production longer and more completely
than hydrocortisone.
Chronic ACTH excess juxtaposed with chronic gluco-
corticoid therapy, often at supraphysiologic doses, might
place patients with 21-OHD at high risk for long-term
complications [5]. The adrenal glands become progressively
hyperplastic in most patients with 21-OHD, and adrenal
tumors, including massive myelolipomas [34], have been
described. In addition to these tumors, a paradoxically
increased prevalence of hypertension has been found in
adolescents [29] and adults [30] with 21-OHD. Reduced
bone mineral density has been found in 21-OHD in most
studies [35, 36], but the degree is moderate, and frank
osteoporosis is uncommon. Other reports note a higher
prevalence of glucose intolerance, obesity, and dyslipidemia
in adults with 21-OHD compared to controls [30], raising
their risk for cardiovascular disease [37]. These health
problems are similar to those maladies associated with poor
quality of life in patients with adrenal insuﬃciency [38]
or cured Cushing’s disease [39] after long-term followup.
Curiously, concomitant androgen excess might mitigate
someofthecatabolicconsequencesofchronicglucocorticoid
exposure, and some beneﬁt is suggested by the observation
that the increased risks appear not large, and major health
problems are not consistently seen.
Above all, the management of the patient with 21-
OHD should recognize that these patients are vulnerable
to all the other diseases that people without this condition
suﬀer, and they require the same general healthcare as any
adult. Women should receive cervical smears, breast exams,
and/or mammograms at the standard ages, and men require
screening for prostate disease. Men and women should
have blood pressure and cholesterol screening, colon cancer
screening, education to avoid smoking and to follow a
healthy lifestyle, and care for acute illnesses. Glucocorticoid
doses should be increased for surgery and for acute illness
when volume depletion from high fever, vomiting, diarrhea,
or poor oral intake occurs—but not for any minor illness or
injury.
3.2. Special Considerations for Women. In women with 21-
OHD, two additional key issues are: (1) whether androgen
excess symptoms are currently a problem, and (2) if the
patient trying to conceive a child now. At a minimum, all
women with 21-OHD must receive replacement doses of
hydrocortisone and ﬂudrocortisone acetate, as would any
other patient with adrenal insuﬃciency. Higher doses and
more potent steroids are used to the extent demanded
by the two issues above. A normal serum testosterone
and absence of androgen excess symptoms indicate ade-
quate glucocorticoid treatment. If not, measurement of
17-hydroxyprogesterone and androstenedione, preferably
in the follicular phase, will help to assess the degree of
control. Chronic normalization of 17-hydroxyprogesterone
indicatesovertreatmentandshouldbeavoided,asvalueswell
above normal are acceptable if androgen concentrations are6 International Journal of Pediatric Endocrinology
controlled and the patient is clinically well. The exception
would be during speciﬁc times when fertility is sought.
Androgen excess is always a problem for these women,
but the degree and its clinical consequences vary tremen-
dously, and there is no reason to expose the woman to
higher doses of corticosteroids if no beneﬁt will be derived.
If control has been poor in childhood, the patient seems
to be more vulnerable to androgen excess, possibly due to
greater adrenal hyperplasia. In addition, women with 21-
OHD often develop a secondary polycystic ovary syndrome
(PCOS), such that androgens and 17-OHP also derive from
the ovaries and persists even after adrenal suppression [40].
Consequently, menses may remain irregular even with good
control of the adrenal axis. If pregnancy is not desired, oral
contraceptive pills provide several beneﬁts, including low-
ering ovarian androgen production, maintaining monthly
menses, and raising sex hormone binding globulin (SHBG),
w h i c hl o w e r sf r e et e s t o s t e r o n ea n dm i t i g a t e ss o m eo ft h e
hyperandrogenism with lower doses of glucocorticoid ther-
apy.Antiandrogentherapyisalogicalapproachfortreatment
of 21-OHD, but with the exception of multidrug regimens
[41],hasreceivedlittleattention.Spironolactone,aneﬀective
and inexpensive agent used to treat other forms of hirsutism
and PCOS, is diﬃcult to use in 21-OHD because it is
both androgen and mineralocorticoid receptor antagonist,
which causes salt loss. With the exception of ﬂutamide
[41], androgen antagonists and 5α-reductase inhibitors
(ﬁnasteride and dutasteride) have not been formally studied
in women with 21-OHD, although some patients have
experimented with regimens containing these drugs. Topical
agents, such as eﬂornithine cream, and mechanical methods
(laser, electrolysis, shaving, and plucking) should not be
neglected.
Forwomenwhoaretryingtobecomepregnant,21-OHD
introduces multiple barriers to conception. In the ﬁrst place,
a minority of women with 21-OHD even attempt to become
pregnant [42], especially those with the most severe or “salt-
wasting” disease [43]. The reasons for their not attempting
pregnancy include vaginal abnormalities, such as inadequate
caliber for coitus or strictures following repair [43]a n d
dyspareunia [42]. Chronic hyperandrogenism adds physical
and psychological challenges for these women. Finally, even
inthosewhowishtobecomemothers,chronicoligoanovula-
tion is common due to high androgens and secondary PCOS
[40], whereas high circulating progesterone [44], which
accumulates 2 steps behind the block, prevents favorable
endometrial maturation and cervical mucus formation [45].
Unlike the multiple options available for women not
attempting pregnancy, the only approach that will improve
the hormonal milieu for ovulation and implantation is
to intensify the glucocorticoid therapy, and the clinician
should not be reluctant to use supraphysiologic dosing for
several months to accomplish this purpose. In addition to
controlling androgen excess, follicular phase progesterone
should be suppressed below 2nmol/L (0.6ng/mL) to favor
fertilizationandimplantation[46].Thisgoalcanbeachieved
with prednisolone or hydrocortisone divided into 2 or more
commonly3dailydoses,asaneveningdoseisoftennecessary
to lower morning serum progesterone adequately. A recent
report demonstrated that 21/23 women with 21-OHD who
desiredpregnancybecamepregnantandhadlivebirthsusing
these regimens [46]. In these women, prenatal therapy is
another issue if their spouse is a carrier; this topic is reviewed
elsewhere.
Despite years of work and innovative surgical ap-
proaches, vaginal reconstruction remains a major problem
in girls with 21-OHD. Often staged procedures are employed
with the goal of urinary hygiene and appropriate clitoral
reduction in the neonate. The trend now is to minimize
surgery in the newborn and child and to leave complete
establishment of an adequate vaginal oriﬁce for when the
woman becomes sexually active. Consequently, many adult
women with 21-OHD face the need for deﬁnitive recon-
struction surgery. The choice of procedure is important,
but the woman must be motivated to use lubricants and
dilatators regularly to obtain the best results and satisfaction.
Traditionalskinorbowelgraftsoftengivesuboptimalresults,
particularly in severely virilized girls [47]. Buccal mucosa
graftshaveshowngoodresultsinserieswithlimitedfollowup
and may become a procedure of choice in the future [48, 49].
3.3. Special Considerations for Men. Men with 21-OHD are
spared the disturbing and disﬁguring eﬀect of contrasexual
hormone excess, which probably renders men with 21-
OHD more prone to neglect their treatment than women.
Unfortunately, men are not spared some of the long-term
health consequences of both 21-OHD and glucocorticoid
therapy, and male physiology and anatomy predispose these
men to other problems. Adrenal androgen excess, when
severe, can suppress gonadotropins and lead to testicular
atrophy and infertility [50]. Reduced fertility has been
observed in small cohorts of men with 21-OHD [51–53], but
aberrant androgen metabolism is only one reason.
The second major cause of infertility and testicular
dysfunction in men with 21-OHD is the presence and
hyperplasia of adrenal rest tumors in the testes (TARTs).
T h ep r e v a l e n c eo fT A R Ti nm e nw i t h2 1 - O H Di sa sh i g ha s
50%, if ascertained by sensitive ultrasonography or magnetic
resonance imaging [51, 54]. These TARTs can become large
and cause pain in addition to impaired testicular function.
Treatment of the TARTs with intensiﬁed glucocorticoid
replacement may cause regression and restoration of normal
sperm counts [55].
At a minimum, men with 21-OHD should have an
annual testicular exam, and screening ultrasonography is
recommend by some authorities. If a mass is found, glu-
cocorticoid treatment is intensiﬁed, such as dexamethasone
0.75–2mg/d [55]. If the mass regresses, the treatment is
continued for several weeks to months until a satisfac-
tory result is obtained. If the mass does not shrink with
dexamethasone, testicular cancer should be excluded by
referral to an urologist. Surgical resection of the TARTs
eﬀectively controls testicular size and Leydig cell function
but fails to restore fertility [56]. It is likely that, when a
large TART is present, the testis is already damaged from
increased pressure in the testicular capsule, which reduces
testicular blood ﬂow and obstructs the seminiferous tubulesInternational Journal of Pediatric Endocrinology 7
[52,53].Consequently,ifpreservationoffertilityisapriority,
the TARTs should be managed early and aggressively with
medical therapy.
Replacement doses of hydrocortisone suﬃce for most
men with 21-OHD, but which laboratory parameters should
be monitored to guide glucocorticoid dosing is not known.
If the 17-OHP is normal, the patient is overtreated, but
values up to about 100nmol/L (∼3,000ng/dL) are probably
a good target. The goal is to have a normal testosterone
and normal gonadal function in the absence of TARTs, and
men with a 17-OHP <3,000 are unlikely to have large TARTs
[57]. Measurement of adrostenedione and gonadotropins
is appropriate if gonadal dysfunction becomes evident to
determine if the adrenals or testes are the dominant source
ofandrogens.ThepresenceofTARTspromptsintensiﬁcation
of therapy to induce regression regardless of apparent
hormonal control.
3.4. Indications for and Consequences of Bilateral Adrenalec-
tomy Adults with 21-OHD. T h ec u r a t i v ep o t e n t i a lo fb i l a t -
eral adrenalectomy for children with 21-OHD has been
recognized, and its utility has been debated aggressively
[58]. In adults with 21-OHD, unique indications have
arisen. First, massive adrenal myelolipomas may develop
[34] and can be bilateral [59] and require surgical removal.
Second, although infertility in both men and women is often
managed with intensiﬁed glucocorticoid therapy, adequate
control cannot be achieved medically in some cases, and
surgical management is required. Restoration of fertility in
women [46, 60]a n dm e n[ 61] with 21-OHD after bilateral
or unilateral adrenalectomy, respectively, has been observed
and should be considered as an alternative approach.
4. Summary
The management of the adult with 21-OHD is a humbling
and perilous process, given the lack of long-term data
and comparative studies. Emerging evidence from centers
with growing experience around the world is beginning to
crystallize a set of guiding principles and concerns. The
mere fact that we are now attentive to the long-term health
consequences of this disease and its treatment attests to
the success in the management of children with 21-OHD,
which has been achieved over the last several decades. The
challenges that remain are now to rene our approach to
the adolescent and adult with 21-OHD, to develop better
adjunctive treatments, and to optimize the quality of life for
these patients. Therapy is expected to change over time as
the norm rather than the exception. With each experience,
we learn a little more about the physiology of adults with
21-OHD. Above all, the needs of the patient, their unique
physiology, and their past experiences should be borne in
mind when developing treatment regimens.
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